Therapy News and Research

RSS

PINC trial to test anti-malarial drug in women with DCIS

Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

3 Mar 2010

Starting radiotherapy as soon as possible could minimise breast cancer recurrence

The longer women wait for radiotherapy after breast cancer surgery, the more chance there is of local recurrence, concludes a study published on bmj.com today.

3 Mar 2010

Common diabetes therapies may increase cancer risk, but more research needed

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

3 Mar 2010

Benefits of aspirin therapy for patients with peripheral artery disease remain unproven

Individuals who were identified as being at increased risk of cardiovascular or cerebrovascular events based on screening for low ankle brachial index, a type of pressure measurement used in the diagnosis of peripheral artery disease, did not significantly reduce their risk of these events with the use of aspirin, according to a study in the March 3 issue of JAMA.

3 Mar 2010

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.

3 Mar 2010

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

3 Mar 2010

Cigarette commercials can encourage smoking among teenagers

A new study shows that the particular content of tobacco marketing resonates with youth and that the vivid imagery in tobacco advertising captures their interest, although teens typically are more resistant to the promotional seduction of other products.

3 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

A DRUG commonly used to prevent and treat bones losing density and becoming brittle - known as osteoporosis - may also help reduce the risk of breast cancer by one third or more according to new research published in the British Journal of Cancer today (Wednesday).

3 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

Concentra expands customer base and reach with the acquisition of Health Now

Effective March 1, Concentra, a national provider of urgent care services, has expanded its customer base and reach with the acquisition of the assets of Cherry Hill Health Care Associates, P.A. in Pennsauken, N.J.

3 Mar 2010

Combination of two targeted therapies effective against subset of gastric cancers: Study

A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

3 Mar 2010

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Biomoda, Inc. (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, "Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation.

2 Mar 2010

Abbott and Enanta advance treatment for Hepatitis C

Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials.

2 Mar 2010

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.

2 Mar 2010

InterMune seeks European marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the European Union (EU). Currently, there are no EMA-approved treatments for IPF in the EU.

2 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

Pre-clinical study of Cardio3 BioSciences' proprietary C-Cath catheter announced

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.

2 Mar 2010

Fluorescence method predicts the efficacy of PDT for Port Wine Stains: Study

It is known that fluctuations in the treatment outcome of photodynamic therapy (PDT) between patients are related to the concentration of photosensitizer in target tissue. The purpose of a study, by Wang et al, published in the February 2010 issue of Experimental Biology and Medicine was to establish a fluorescence method not only providing a semi-quantitative measurement of photosensitizer concentration but also predicting the efficacy of PDT for Port Wine Stains (PWS).

2 Mar 2010

Therapy News and Research

PINC trial to test anti-malarial drug in women with DCIS

Starting radiotherapy as soon as possible could minimise breast cancer recurrence

Common diabetes therapies may increase cancer risk, but more research needed

Benefits of aspirin therapy for patients with peripheral artery disease remain unproven

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Cigarette commercials can encourage smoking among teenagers

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Concentra expands customer base and reach with the acquisition of Health Now

Combination of two targeted therapies effective against subset of gastric cancers: Study

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Abbott and Enanta advance treatment for Hepatitis C

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

InterMune seeks European marketing approval for pirfenidone

ArQule reports net loss of $36,136,000 for 2009

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

Pre-clinical study of Cardio3 BioSciences' proprietary C-Cath catheter announced

Fluorescence method predicts the efficacy of PDT for Port Wine Stains: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News